First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun Vasant Balar(NYU Langone Health), Daniel Castellano(Hospital Universitario 12 De Octubre), Peter H. O’Donnell(University of Chicago Medical Center), Petros Grivas(Cleveland Clinic), Jacqueline Vuky(Oregon Health & Science University), Thomas Powles(Queen Mary University of London), Elizabeth R. Plimack(Fox Chase Cancer Center), Noah M. Hahn(Sidney Kimmel Comprehensive Cancer Center), Ronald de Wit(Erasmus MC Cancer Institute), Lei Pang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary J. Savage(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen J. O’Keefe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Joaquim Bellmunt(Dana-Farber Cancer Institute)
Cited by 1,338
Abstract
Related Papers
No related papers found
Powered by citation graph analysis